Validity of brain MRI as the primary outcome criterion in multiple sclerosis phase II clinical trials

被引：0
|
作者：
Liedtke, W [1 ]
Limmroth, V [1 ]
机构：
[1] NIH,OFF DIRECTOR,LAB DIAGNOST RADIOL RES,BETHESDA,MD 20892
来源：
ANNALS OF NEUROLOGY | 1996年 / 39卷 / 02期
关键词：
D O I：
10.1002/ana.410390221
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：276 / 276
页数：1
相关论文
共 50 条
  • [41] Appropriate design and outcome measures in multiple sclerosis clinical trials - Response
    Khan, OA
    Tselis, AC
    Kamholz, JA
    Garbern, JY
    Lewis, RA
    Lisak, RP
    EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (05) : 505 - 506
  • [42] Role of MRI in multiple sclerosis II: Brain and spinal cord atrophy
    Zivadinov, R
    Bakshi, R
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 647 - 664
  • [43] Cerebellar volume as an outcome measure in therapeutic trials of primary progressive multiple sclerosis
    Inglese, M.
    Petracca, M.
    Saiote, C.
    Ruggieri, S.
    Fabian, M.
    Howard, J.
    Riley, C.
    Krieger, S.
    Miller, A.
    Lublin, F.
    Sormani, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 198 - 199
  • [44] A USEFUL ENTRY CRITERION FOR MULTIPLE-SCLEROSIS CLINICAL-TRIALS TO PREVENT PROGRESSION
    MYERS, LW
    LEAKE, BD
    ELLISON, GW
    ANNALS OF NEUROLOGY, 1995, 38 (02) : 339 - 339
  • [45] Worsening on DSS is not a useful entry criterion for multiple sclerosis clinical trials to prevent progression
    Myers, LW
    Leake, BD
    Ellison, GW
    ANNALS OF NEUROLOGY, 1996, 40 (03) : T240 - T240
  • [46] MRI as primary endpoint of clinical trials should MRI be the PEP of phase III trials in MS? YES
    Sormani, M. P.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
  • [47] Spinal cord atrophy as a primary outcome measure in primary progressive multiple sclerosis neuroprotective trials
    Cawley, N.
    Abdel-Aziz, K.
    Schneider, T.
    Altmann, D.
    Wheeler-Kingshott, C. A. M.
    Miller, D. H.
    Thompson, A. J.
    Ciccarelli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 189 - 190
  • [48] A three-outcome design for phase II clinical trials
    Sargent, DJ
    Chan, V
    Goldberg, RM
    CONTROLLED CLINICAL TRIALS, 2001, 22 (02): : 117 - 125
  • [49] Daclizumab phase I/II trial in relapsing-remitting multiple sclerosis: MRI and clinical results
    Rose, J.
    Burns, J.
    Bjorklund, J.
    Klein, J.
    Watt, H.
    Carlson, N.
    MULTIPLE SCLEROSIS, 2006, 12 : S105 - S105
  • [50] The role of MRI in clinical trials of multiple sclerosis: Comparison of image processing techniques
    Evans, AC
    Frank, JA
    Antel, J
    Miller, DH
    ANNALS OF NEUROLOGY, 1997, 41 (01) : 125 - 132
12345